Transforming The Status Quo In Cell Therapy Manufacturing

Current CAR-T therapy manufacturing relies on manual or semi-automated processes, leading to suboptimal biological performance and increased variability. This inflexibility often forces vital biological processes to adapt to manufacturing limitations rather than the other way around. Oribiotech is changing this paradigm by prioritizing biology first, developing an innovative platform specifically designed for the complexities of cell and gene therapies. This approach aims to automate and optimize manufacturing, tackling issues of scalability, quality, and cost.

Discover how Ori's technology delivers industry-leading biological performance. Dive into this collection of case studies to learn more.